Debt-to-equity of LENZ Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
LENZ Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • LENZ Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 6%, a 46% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

LENZ Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 6% -5.1% -46% 30 Sep 2025
Q2 2025 4.9% -44% -90% 30 Jun 2025
Q1 2025 4.8% +1075% 31 Mar 2025
Q4 2024 6% +77% 31 Dec 2024
Q3 2024 11% +113% 30 Sep 2024
Q2 2024 48% -20% -30% 30 Jun 2024
Q1 2024 -1070% -1086% -6927% 31 Mar 2024
Q4 2023 -71% -79% -1024% 31 Dec 2023
Q3 2023 -102% -106% -2162% 30 Sep 2023
Q2 2023 69% +64% +1434% 30 Jun 2023
Q1 2023 16% +12% +304% 31 Mar 2023
Q4 2022 7.7% 31 Dec 2022
Q3 2022 4.9% 30 Sep 2022
Q2 2022 4.5% 30 Jun 2022
Q1 2022 3.9% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.